Navigation Links
Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis.  OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy. Patients with liver failure and decompensated cirrhosis   may present with confusion and coma,  a frequent complication known as acute hepatic encephalopathy (AHE) and an indicator of poor long-term survival.

Orphan Drug designation applies to a compound being developed to treat a rare medical condition. It offers a number of potential incentives, which may include a seven-year period of U.S. marketing exclusivity from the date of marketing authorization, funding for clinical studies, study design assistance, waiver of FDA user fees, and tax credits for clinical research.  The Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs often qualify for priority review, thereby expediting the FDA review process.

"Unlike current treatments that target the production of ammonia in the intestinal tract, OCR-002 directly reduces toxic levels of ammonia in the blood that lead to severe neurologic complications including coma. AHE is associated with substantial morbidity and mortality, and OCR-002 has the potential to be a novel therapeutic option for these patients," stated Dr. Laurent Fischer, CEO of Ocera Therapeutics. "Our receipt of Orphan Drug status and Fast Track designation for OCR-002 reinforce the clinical unmet need in AHE, and demonstrate the imp
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
2. Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
3. Dr Stephan Rietiker Joins BioCeramic Therapeutics
4. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
5. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
6. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
7. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
8. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
10. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing ... round of seed financing from friends and family investors. ... develop a novel sustained-release product for ophthalmology. , "We ... their commitment to this important work," said Dr. Ken ... of many areas in which innovations in drug delivery ...
(Date:7/29/2014)... NASA technologists have hurdled a number of significant ... already revolutionary observing technology originally created for the ... by Principal Investigator Harvey Moseley, a scientist at ... has demonstrated that electrostatically actuated microshutter arrays ... voltage are as functional as the current ...
(Date:7/29/2014)... JOLLA, Calif. , July 29, 2014 ... diagnostic and therapeutic company focused on extending the healthy, ... hired Franz Och , Ph.D., an expert in ... Data Scientist. Och comes to HLI from Google where ... Google Translate. He will report directly to HLI Co-Founder ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... 2011 Arecor, the leading company ... and vaccines, is pleased to announce the appointment ... Howell will be responsible for the operations of ... Arecor,s upward growth curve ensuring the company continues ...
... Nov. 10, 2011 Avaxia Biologics, Inc. , ... act locally within the gastrointestinal tract, announced today that ... of a Series A angel-led financing. Cherrystone Angels of ... Boston Harbor Angels and other undisclosed individuals. Mr. Robert ...
... Discovery Laboratories, Inc. (Nasdaq: DSCO ), ... respiratory critical care, today reports financial results for the third ... of the SURFAXIN® and AFECTAIR™ programs.  The Company will host ... call details are below. Selected third quarter highlights ...
Cached Biology Technology:Arecor Appoints Dr. Sarah Howell as Chief Operating Officer 2Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 3Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 4Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 5Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 6Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 7Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 8Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 9
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... , July 30, 2014 NexID ... and liveness detection solutions for the biometric authentication ... industry consortium revolutionizing online authentication with standards for ... Cornett , "The decision to join FIDO Alliance ... authentication pervasive in use. We believe the FIDO ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
... If you would like to receive Science Picks via e-mail, ... to receive it, please e-mail kcapelli@usgs.gov . October ... Sumatra Earthquakes, DOI Prepared to Address Climate Change, Water is ... of Seismic Proportions, Forget the Garlic Necklace! Learn More about ...
... attention to National Child Health Day (today), the Preventive Cardiovascular ... consumer survey and launched a campaign to educate families about ... The national survey revealed that more than three in ... heart disease do not begin until adulthood. ...
Cached Biology News:NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3USGS Science Picks 2USGS Science Picks 3USGS Science Picks 4USGS Science Picks 5USGS Science Picks 6USGS Science Picks 7USGS Science Picks 8USGS Science Picks 9Americans concerned about heart health, but not proactive enough to prevent it 2
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... 4000 incorporates the critical design features demanded ... biomarker research. The Series 4000 delivers improved ... biomarker discoveries to biomarker assays all on ... designed to fit into the research plans ...
Gelatin 100 mm Culture Dishes...
Biology Products: